- AU$48.50bn
- AU$47.32bn
- $5.65bn
ASX-listed Resmed rises; Citi lifts PT on margin expansion prospect
ResMed's Australia-listed shares hit record high on strong earnings
ResMed's Australia-listed shares hit record high on strong earnings
Australia's ResMed slips after rival Apnimed posts positive clinical trial results
ASX-listed ResMed slips after Jarden cuts PT
Resmed's Australian shares fall after insider Ghoshal sells stock
Resmed's Australia shares fall; Macquarie hikes PT
Australia-listed shares of ResMed climb to 1-year high as analysts hike PT
ASX-listed shares of ResMed jump on strong quarterly results
ASX-listed shares of ResMed sink after Lilly's drug reduces sleep apnea severity
Australian health stocks drop most in 4 months; CSL falls after drug trial fails
Philips' FDA agreement to aid earnings for Australia's ResMed - Citi
Australia's CSL tanks as Novo Nordisk's kidney trial success stokes competition concerns
ASX-listed Resmed set for worst day in 3 years on weak Q4 results
ASX-listed Resmed on track for worst day in three years on earnings miss
ASX-listed ResMed climbs on upbeat quarterly results
ASX-listed ResMed climbs on upbeat quarterly results
Citi sees ResMed's recent Medifox Dan acquisition as EPS accretive
ResMed's Australia shares top losses on ASX200 as Q3 results miss estimates